Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Glaucoma
Interventions: Travoprost, Latanoprost; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma, Hypertension, Obesity
Interventions: Asthma education; Behavioral
Lead sponsor: Duquesne University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 231 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension, Diabetes Mellitus, Stroke, Myocardial Ischemia, Heart Failure, Asthma
Interventions: Medication Management report, Care manager email notices; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: Oklahoma State University Center for Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
Interventions: Spironolactone, BP medication uptitration; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Disease
Interventions: Treatment as usual (TAU) + Internet, TAU + ElderTree; Other · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 65 Years and older
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetes Mellitus, Type 2, Prediabetic State, Hypertension, Prehypertension, Obesity
Interventions: FeatForward App (on study smartphone); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Charlestown, Massachusetts • Revere, Massachusetts

Conditions: Glaucoma
Interventions: Glaucoma Diagnosis, Name: Neucodia; Device
Lead sponsor: Synabridge Corporation; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • New Haven, Connecticut • Raritan, New Jersey + 2 more

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: Oral treprostinil, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Pulmonary Vascular Resistance Abnormality
Interventions: Measuring VA Coupling; Procedure
Lead sponsor: Hythem Nawaytou; Other
Eligibility: 1 Year to 21 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: San Francisco, California • Minneapolis, Minnesota

Conditions: Resistant Hypertension
Interventions: Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 41
States / cities: Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more

Conditions: Hypercortisolism
Interventions: Relacorilant, Placebo; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Stanford, California • Torrance, California + 19 more

Conditions: Postpartum, Postpartum Depression (PPD), Hypertension Disorders in Pregnancy, Postpartum Anxiety, Postpartum Care, Care Coordination, Care Gaps
Interventions: Postpartum Doula Support in the NICU; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 14
States / cities: Newark, Delaware • Voorhees Township, New Jersey • Bryn Mawr, Pennsylvania + 9 more

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Conditions: Pulmonary Arterial Hypertension
Interventions: UT-15C SR, treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 1,540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2022
U.S. locations: 3
States / cities: Birmingham, Alabama • La Jolla, California • New York, New York

Conditions: Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
Interventions: miLens system; Device
Lead sponsor: Smartlens, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Fullerton, California • Petaluma, California • Torrance, California

Conditions: Hypertension (HTN), Cardiometabolic Diseases
Interventions: Low Salt Diet, High Salt Diet, Saline Infusion; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension, Diabetes, Hypercholesterolemia
Interventions: education intervention; Behavioral
Lead sponsor: Durham VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Gestational Hypertension
Interventions: Nokia-Withings BPM Connect Blood Pressure Monitor, Smartwatch Devices; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Sturge Weber Syndrome
Interventions: Everolimus; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 2 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Hypertension, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Arterial Hypertension
Interventions: Anastrozole, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Providence, Rhode Island

Search by objective public record fields.

Effects of Anti-Glaucoma Medications on the Ocular Surface

Implementation of an Asthma Program to Improve Asthma Identification and Education in Children

Clinical Decision Support for Medication Management and Adherence

A Retrospective Review of the Seasonality of Pre-Eclampsia

Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

Multiple Chronic Conditions for Older Adults

Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients

Instrument for Glaucoma Early Detection and Monitoring

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

PV Loop and Pulmonary Hypertension

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Postpartum Care in the NICU Multi-Site

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

African Descent and Glaucoma Evaluation Study

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

Medication Adherence With Polyglot Meducation

Digital Solutions to Reduce Maternal Morbidity and Mortality in Pregnant Refugee Women

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

Anastrozole in Patients With Pulmonary Arterial Hypertension